The tumor almost always comes back, angrier than before.
For more than twenty years, glioblastoma has resisted every advance medicine could offer, leaving patients with a median survival of less than fifteen months and physicians with little more than the same blunt instruments of surgery, radiation, and chemotherapy. Now, researchers at McMaster University have developed a CAR T cell therapy that reprograms the immune system to hunt a specific protein — uPAR — found on both the tumor and the biological scaffolding that allows it to return. Published in Science Translational Medicine and already moving toward clinical trial discussions, the work represents the first genuinely new principle of attack against this disease in a generation — a reminder that even the longest stases in medicine can, at last, break.
- Glioblastoma has defied meaningful treatment advances for over two decades, with nearly every patient facing death within fifteen months of diagnosis.
- The tumor's relentless recurrence — driven by the support structures surrounding it, not just the cancer cells themselves — has made conventional therapies feel like temporary delays rather than real solutions.
- McMaster researchers have engineered immune cells to target uPAR, a protein present on both the tumor and its scaffolding, striking the disease at the root of why it keeps coming back.
- Preclinical results, published in a high-impact journal and developed through a partnership with Canada's National Research Council, have cleared the first credibility threshold in a field hungry for good news.
- Clinical trial discussions are now underway, and the same uPAR target is drawing independent interest from researchers studying lung and pancreatic cancers, suggesting this breakthrough may reach far beyond the brain.
Glioblastoma kills most of the people it touches. Median survival from diagnosis is under fifteen months, and the standard tools — surgery, radiation, chemotherapy — almost never prevent the tumor from returning, often more resistant than before. For more than twenty years, oncologists have had little new to offer. That may be changing.
Researchers at McMaster University have developed a therapy called a uPAR Chimeric CAR T cell, which reprograms the body's own immune cells to seek out and destroy a specific protein — the urokinase receptor, or uPAR — found on glioblastoma tumors. Critically, uPAR appears not only on the cancer cells themselves but also on the surrounding support structures that allow the tumor to persist and regrow after treatment. By targeting both, the therapy aims to address the core reason glioblastoma recurs so relentlessly. The work, conducted in partnership with Canada's National Research Council, was published in Science Translational Medicine.
The discovery sits within a broader convergence: scientists at Memorial Sloan Kettering and Columbia University have independently identified uPAR as a promising target in lung and pancreatic cancers, and collaborative efforts across institutions are already taking shape. Principal investigator Sheila Singh holds appointments at both McMaster and King's College London, positioning the research at the intersection of North American and European oncology.
The road from laboratory to patient remains long. But clinical trial discussions are underway, the therapy has been patented, and commercial pathways are being explored. For first author William Maich, a postdoctoral fellow who has come to know glioblastoma patients through McMaster's bequeathal program, the stakes are deeply personal. For the first time in twenty years, there is something concrete — and genuinely different — to work toward.
Glioblastoma kills most of the people who get it. The median survival from diagnosis is less than fifteen months. Surgery, radiation, chemotherapy—the standard arsenal—can slow it down, but the tumor almost always comes back, angrier and more resistant than before. For more than twenty years, oncologists have had little new to offer their patients. That stasis may be ending.
Researchers at McMaster University have developed an immunotherapy that, in early laboratory work, can eliminate glioblastoma tumors in ways the current standard treatments cannot. The drug candidate, called a uPAR Chimeric CAR T cell, represents a fundamentally different approach to the disease. Rather than attacking the cancer cells directly with poison or radiation, it reprograms the body's own immune system to recognize and destroy a specific protein found on the surface of glioblastoma cells—a protein called the urokinase receptor, or uPAR. The innovation came through a partnership with scientists at Canada's National Research Council, who developed the antibodies that make the therapy possible.
What makes this approach potentially transformative is that uPAR appears not just on the cancer cells themselves, but also on the support cells surrounding the tumor—the biological scaffolding that allows glioblastoma to persist and regrow after treatment. By targeting both the tumor and its infrastructure, the new therapy could address the fundamental reason glioblastoma recurs so relentlessly. The preclinical findings were published in Science Translational Medicine, a high-impact journal that signals serious scientific credibility.
Sheila Singh, a professor of surgery at McMaster and the principal investigator on the study, frames the work as part of a larger shift in cancer research. Scientists at Memorial Sloan Kettering and Columbia University have independently identified uPAR as a promising target in lung and pancreatic cancers—diseases that, like glioblastoma, have resisted conventional treatment. This convergence is already sparking collaborative efforts to develop therapies that might work across multiple hard-to-treat malignancies. Singh herself holds a dual appointment as a professor of neuro-oncology and neurosurgery at King's College London, positioning her research at the intersection of North American and European cancer science.
The path from laboratory success to patient treatment is long and uncertain. But discussions about moving this discovery toward clinical trials are already underway. Singh's group has patented the therapy and is exploring both commercial and clinical pathways. For William Maich, a postdoctoral fellow in Singh's lab and the first author on the study, the prospect carries personal weight. Through McMaster's bequeathal program, he has come to know glioblastoma patients and their families—people living under the shadow of a diagnosis that offers almost no hope of long-term survival. The chance to offer them something genuinely new, something that works on a different principle than the treatments that have failed them, is what drives the work forward. "It would be a dream come true," Maich said, "to have some of my work help glioblastoma patients." The dream remains preclinical. But for the first time in two decades, there is something concrete to dream about.
Citas Notables
The standard of glioblastoma care has remained largely unchanged for over two decades, and the disease remains uniformly fatal because of it.— Sheila Singh, McMaster University
It would be a dream come true for me to have some of my work help glioblastoma patients.— William Maich, postdoctoral fellow at McMaster
La Conversación del Hearth Otra perspectiva de la historia
Why does glioblastoma come back so aggressively after standard treatment?
Because the tumor doesn't exist in isolation. It's surrounded by support cells—a whole ecosystem that feeds it and protects it. Surgery, radiation, and chemotherapy can damage the cancer cells, but they don't dismantle that infrastructure. So the tumor regrows from what's left.
And this new therapy targets both?
Exactly. By going after uPAR—a protein on both the cancer cells and the support cells—it's trying to eliminate not just the tumor, but the conditions that allow it to come back.
How long until patients can actually receive this treatment?
That's the honest answer: we don't know yet. Preclinical work is one thing. Clinical trials are another. But the fact that conversations about moving forward are already happening suggests the researchers believe in it enough to pursue the regulatory pathway.
What's striking to you about the timing—that three separate research groups landed on uPAR?
It suggests the science is pointing somewhere real. When independent teams converge on the same target, it's usually because the biology is actually there. That gives me confidence this isn't a dead end.
For the researchers themselves, what's at stake?
For Maich especially, it's personal. He knows these patients. He's watched them exhaust their options. The chance to offer them something genuinely new—not just a variation on what's already failed—that's what makes the work meaningful.